Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya
Status:
COMPLETED
Trial end date:
2024-08-14
Target enrollment:
Participant gender:
Summary
This study investigates the pharmacokinetics of Artesunate (AS) and dihydroartemisinin (DHA), the active metabolite of Artesunate, following intravaginal use at the dosing and frequency being studied for cervical precancer treatment. A secondary objective is to investigate safety among study participants.
Phase:
PHASE1
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)